Halloran Makes the Inc. 5000 for the Fourth Year in a Row

Wed, Aug 16th 2017
We are thrilled to announce that Halloran has been recognized on the Inc. 5000 list for the fourth year running. Each year, Inc. magazine names the fastest growing private companies on a prestigious list that exemplifies a high level of success and transformation.
Read More

Halloran Advises SEEK in Preparation for First Trial of Vaccine to Protect Against Mosquito-Borne Diseases

Tue, Feb 21st 2017
Halloran announces the successful submission of an Investigational New Drug (IND) application by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, for a novel vaccine designed to prevent infection of mosquito-transmitted disease, such as Zika, malaria, West Nile virus and dengue, and to hinder transmission of such infections.
Read More